Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Assets (2016 - 2025)

Fortress Biotech has reported Current Assets over the past 13 years, most recently at $123.8 million for Q4 2025.

  • Quarterly results put Current Assets at $123.8 million for Q4 2025, up 37.04% from a year ago — trailing twelve months through Dec 2025 was $123.8 million (up 37.04% YoY), and the annual figure for FY2025 was $123.8 million, up 37.04%.
  • Current Assets for Q4 2025 was $123.8 million at Fortress Biotech, up from $118.5 million in the prior quarter.
  • Over the last five years, Current Assets for FBIO hit a ceiling of $346.5 million in Q4 2021 and a floor of $86.3 million in Q3 2024.
  • Median Current Assets over the past 5 years was $127.3 million (2023), compared with a mean of $191.8 million.
  • Biggest five-year swings in Current Assets: soared 100.25% in 2021 and later tumbled 62.08% in 2023.
  • Fortress Biotech's Current Assets stood at $346.5 million in 2021, then plummeted by 33.49% to $230.4 million in 2022, then crashed by 49.22% to $117.0 million in 2023, then fell by 22.77% to $90.4 million in 2024, then skyrocketed by 37.04% to $123.8 million in 2025.
  • The last three reported values for Current Assets were $123.8 million (Q4 2025), $118.5 million (Q3 2025), and $110.4 million (Q2 2025) per Business Quant data.